Overview

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-18
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Phase:
PHASE3
Details
Lead Sponsor:
Bristol-Myers Squibb